Jawed Rohil, Bhatti Huma, Khan Adnan
Department of Biomedical Engineering, College of Engineering and Applied Sciences, Nanjing University, Nanjing, 210023, China.
School of Chemistry and Chemical Engineering, State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, 210023, China.
Clin Transl Oncol. 2025 May;27(5):1867-1886. doi: 10.1007/s12094-024-03754-4. Epub 2024 Oct 26.
Lung cancer (LC) is the leading cause of cancer-related deaths and the second most commonly diagnosed malignancy worldwide. Lung adenocarcinoma (LUAD) and lung squamous cell LC (LUSCC) are the most common subtypes of non-small cell LC (NSCLC). Early diagnosis of LC can be challenging due to a lack of biomarkers. The overall survival (OS) of patients with NSCLC is still poor despite the enormous efforts that have been made to develop novel treatments. Understanding fundamental molecular and genetic mechanisms is necessary to develop new therapeutic approaches for NSCLC. A recently identified type of programmed cell death known as ferroptosis is one potential approach. Ferroptosis causes oxidative damage and the death of cancerous cells by peroxidizing unsaturated phospholipids and accumulating reactive oxygen species (ROS) in an iron-dependent manner. Ferroptosis-related gene (FRG) signatures have recently been evaluated for their ability to predict patient OS and prognosis. These analyses show FRGs are involved in cancer progression, and may serve as promising biomarkers for tumor diagnosis and therapy. Moreover, we summarize the current pharmaceutical options of ferroptosis induction and their underlying molecular mechanism in LC. Therefore, this review aims to provide a comprehensive summary of FRG-based prognostic models, their associated metabolic and signaling pathways, and promising therapeutic options for ferroptosis induction in NSCLC.
肺癌（LC）是癌症相关死亡的主要原因，也是全球第二常见的诊断恶性肿瘤。肺腺癌（LUAD）和肺鳞状细胞癌（LUSCC）是非小细胞肺癌（NSCLC）最常见的亚型。由于缺乏生物标志物，LC的早期诊断可能具有挑战性。尽管在开发新治疗方法方面付出了巨大努力，但NSCLC患者的总生存期（OS）仍然很差。了解基本的分子和遗传机制对于开发NSCLC的新治疗方法是必要的。最近发现的一种程序性细胞死亡类型——铁死亡是一种潜在的方法。铁死亡通过过氧化不饱和磷脂并以铁依赖的方式积累活性氧（ROS），导致氧化损伤和癌细胞死亡。最近对铁死亡相关基因（FRG）特征预测患者OS和预后的能力进行了评估。这些分析表明，FRG参与癌症进展，并可能作为有前景的肿瘤诊断和治疗生物标志物。此外，我们总结了目前LC中铁死亡诱导的药物选择及其潜在的分子机制。因此，本综述旨在全面总结基于FRG的预后模型、其相关的代谢和信号通路，以及NSCLC中铁死亡诱导的有前景的治疗选择。
